Big Moves in Oncology: Takeda Pays $1.2B Upfront for Innovent
Takeda Pharmaceutical has signed a blockbuster deal with China’s Innovent Biologics, valued at $11.4 billion, to co-develop and commercialise cancer therapies globally, including in the U.S., according to Reuters.
👉 The collaboration focuses on immuno-oncology and antibody-drug conjugate therapies, notably with Innovent’s lead candidates IBI363 and IBI34.
Key deal highlights:
– $1.2B upfront payment (including $100M equity investment by Takeda)
– Up to $10.2B in potential milestone payments tied to clinical and commercial success
– Targets non-small cell lung cancer and colorectal cancer, with late-stage investigational assets
This deal signals a major push by big pharma partnering with Asian biotech into the global oncology arena, leveraging cutting-edge ADC and immuno-oncology pipelines.Strategic vision or aggressive early-stage gamble?
Either way, cancer treatment just got more competitive.
Explore more
🎤 Career – Real career stories and job profiles of life science professionals. Discover current opportunities for students and researchers.
💼 Jobs – The latest job openings and internship alerts across academia and industry.
📢 Advertise with BioPatrika – Reach the Right Audience, Fast!
🛠️ Services – Regulatory support, patent filing assistance, and career consulting services.
